CN117320715A - 用于治疗过度增殖性疾病的化合物 - Google Patents

用于治疗过度增殖性疾病的化合物 Download PDF

Info

Publication number
CN117320715A
CN117320715A CN202280035450.7A CN202280035450A CN117320715A CN 117320715 A CN117320715 A CN 117320715A CN 202280035450 A CN202280035450 A CN 202280035450A CN 117320715 A CN117320715 A CN 117320715A
Authority
CN
China
Prior art keywords
alkyl
thiazol
indol
methyl
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280035450.7A
Other languages
English (en)
Chinese (zh)
Inventor
赫克托·加西亚帕尔默
伊莎贝尔·普伊格博雷尔
何塞普·塔伯内罗卡图拉
卡洛斯·加尔迪亚诺坎塔多尔
蒂亚戈·穆尼奥斯-托雷罗洛佩斯-伊瓦拉
泽维尔·巴里尔阿隆索
塞尔吉奥·鲁伊斯卡莫纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat de Barcelona UB
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Original Assignee
Universitat de Barcelona UB
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat de Barcelona UB, Institucio Catalana de Recerca i Estudis Avancats ICREA, Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron filed Critical Universitat de Barcelona UB
Publication of CN117320715A publication Critical patent/CN117320715A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202280035450.7A 2021-04-21 2022-04-21 用于治疗过度增殖性疾病的化合物 Pending CN117320715A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382343.8 2021-04-21
EP21382343.8A EP4079304A1 (en) 2021-04-21 2021-04-21 Compounds for use in the treatment of hyperproliferative disorders
PCT/EP2022/060579 WO2022223704A1 (en) 2021-04-21 2022-04-21 Compounds for use in the treatment of hyperproliferative disorders

Publications (1)

Publication Number Publication Date
CN117320715A true CN117320715A (zh) 2023-12-29

Family

ID=75674747

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280035450.7A Pending CN117320715A (zh) 2021-04-21 2022-04-21 用于治疗过度增殖性疾病的化合物

Country Status (11)

Country Link
US (1) US20240208998A1 (enExample)
EP (2) EP4079304A1 (enExample)
JP (1) JP2024515705A (enExample)
KR (1) KR20240013112A (enExample)
CN (1) CN117320715A (enExample)
AU (1) AU2022260529A1 (enExample)
BR (1) BR112023021959A2 (enExample)
CA (1) CA3216090A1 (enExample)
IL (1) IL307868A (enExample)
MX (1) MX2023012457A (enExample)
WO (1) WO2022223704A1 (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2609912T3 (es) * 2007-06-22 2017-04-25 Hydra Biosciences, Inc. Compuestos de 2,6-dioxo, -2,3-dihidro-1h-purina útiles para el tratamiento de trastornos relacionados con la actividad del canal trpa1

Also Published As

Publication number Publication date
JP2024515705A (ja) 2024-04-10
WO2022223704A1 (en) 2022-10-27
IL307868A (en) 2023-12-01
MX2023012457A (es) 2023-11-22
EP4079304A1 (en) 2022-10-26
CA3216090A1 (en) 2022-10-27
KR20240013112A (ko) 2024-01-30
AU2022260529A1 (en) 2023-11-09
US20240208998A1 (en) 2024-06-27
BR112023021959A2 (pt) 2023-12-26
EP4326262A1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
CN108697714B (zh) 稠合嘧啶化合物或其盐
CN102816175B (zh) 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
EP2945623B1 (en) Hedgehog pathway signaling inhibitors and therapeutic applications thereof
JP5116686B2 (ja) Ｃｃ−１０６５類似体の調製方法及び調製用化合物
KR102058366B1 (ko) 축합 피리미딘 화합물 또는 그의 염
CN105683195B (zh) 喹啉取代的化合物
JP6903635B2 (ja) 抗増殖活性を有するピペリジノベンゾジアゼピン化合物
JP2019019131A (ja) 繊維芽細胞成長因子受容体の阻害剤
CA2195697A1 (en) Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof
KR20180086221A (ko) Ror-감마의 조절물질
WO2018233553A1 (zh) 稠合双环类化合物及其在药物中的应用
CN105829285A (zh) 喹唑啉酮和异喹啉酮衍生物
CN113454081A (zh) 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途
CN108495855B (zh) 作为mnk抑制剂的稠合噻唑并嘧啶衍生物
KR101754664B1 (ko) 치환된 피리도〔2,3-ｄ〕피리미딘-7(8ｈ)-온스 및 이의 치료 용도
AU2024263367A1 (en) Antibody-drug conjugate
CN120092010A (zh) 多环类聚（adp核糖）聚合酶选择性抑制剂
CN117320715A (zh) 用于治疗过度增殖性疾病的化合物
JP2019510055A (ja) シクロフィリンの阻害のための化合物及びその使用
CN112300154A (zh) 一类含氮杂环化合物、其制备方法和用途
EA048831B1 (ru) Соединения для применения при лечении гиперпролиферативных заболеваний
KR20200110322A (ko) Tp53을 활성화시키는 치료제들로서의 1,2,3',5'-테트라하이드로-2'h-스피로[인돌레-3,1'-피르롤로[3,4-c]피르롤레]-2,3'-디온 화합물들
IDREES et al. Facile synthesis, characterization and antimicrobial activities of novel 6-amino triazolo-thiadiazoles integrated with benzofuran and pyrazole moieties
WO2022222951A1 (zh) 芳香稠合环类衍生物及其制备方法和用途
HK1262235A1 (en) Novel condensed pyrimidine compound or salt thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination